← Leaderboards
Robert Roy Henry
University Of California San Diego
$4,115,619
Attributed
$5,126,728
Total exposure
29
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $642.7K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$5,126,728 · 28
VA$0 · 1
By mechanism
R01$3,142,219 · 3
M01$1,984,509 · 25
I01$0 · 1
Top collaborators
- Francisco J Villarreal5 shared
Most similar at University Of California San Diego
Same institution · by research overlap
- Odile A Mathieu-Costello$1,477,488
- Paul M Quinton$2,014,405
- G Kim Prisk$7,014,931
- Angela Cortney Henderson$987,848
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectGlucose MetabolismStriated MusclesInsulinObesityNoninsulin Dependent Diabetes MellitusMuscle MetabolismBody CompositionDrug Screening /EvaluationHuman Therapy EvaluationDiabetes Mellitus TherapyTroglitazoneDiabetes MellitusPharmacokineticsGene ExpressionFatty AcidsAdipose TissueResourcesInsulin Sensitivity /ResistanceSourceHuman TissueFundingLipid Metabolism
Grant awards (110)
Epicatechin and derivatives to preserve muscle structure function in diabetes$344,875
R01 · FY2017 · DK
Epicatechin and derivatives to preserve muscle structure function in diabetes$344,875
R01 · FY2016 · DK
Epicatechin and derivatives to preserve muscle structure function in diabetes$344,875
R01 · FY2015 · DK
Function of the Myo-adipo Axis in Human Obesity and Type 2 Diabetes$0
I01 · FY2015 · VA · contact PI
Epicatechin and derivatives to preserve muscle structure function in diabetes$344,875
R01 · FY2014 · DK
Function of the Myo-adipo Axis in Human Obesity and Type 2 Diabetes$0
I01 · FY2014 · VA · contact PI
Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin$642,719
R01 · FY2013 · AT · contact PI
Function of the Myo-adipo Axis in Human Obesity and Type 2 Diabetes$0
I01 · FY2013 · VA · contact PI
Function of the Myo-adipo Axis in Human Obesity and Type 2 Diabetes$0
I01 · FY2012 · VA · contact PI
TARGETING INFLAMMATION USING SALSALATE FOR TYPE 2 DM$4,660
M01 · FY2010 · RR · contact PI
EFFECT OF 12 WKS OF COLESEVELAM ON INSULIN SENSITIVITY & ORAL GLUCOSE ABSORPTION$26,103
M01 · FY2008 · RR · contact PI
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$21,982
M01 · FY2008 · RR · contact PI
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$19,234
M01 · FY2008 · RR · contact PI
COMPARISON OF IN VITRO AND IN VIVO MEASURES OF INSULIN IN POLYCYSTIC OVARIES$2,748
M01 · FY2008 · RR · contact PI
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$156,979
M01 · FY2007 · RR · contact PI
EFFECT OF 12 WKS OF COLESEVELAM ON INSULIN SENSITIVITY & ORAL GLUCOSE ABSORPTION$41,861
M01 · FY2007 · RR · contact PI
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$37,210
M01 · FY2007 · RR · contact PI
MECHANISMS OF EDEMA AND WEIGHT GAIN WITH PIOGLITAZONE$34,884
M01 · FY2007 · RR · contact PI
COMBINATION THERAPY WITH ROSIGLITAZONE AND METFORMIN FOR TYPE 2 DIABETES$22,093
M01 · FY2007 · RR · contact PI
COMPARISON OF IN VITRO AND IN VIVO MEASURES OF INSULIN IN POLYCYSTIC OVARIES$5,038
M01 · FY2007 · RR · contact PI
COMBINATION THERAPY WITH ROSIGLITAZONE AND METFORMIN FOR TYPE 2 DIABETES$140,323
M01 · FY2006 · RR · contact PI
MECHANISMS OF EDEMA AND WEIGHT GAIN WITH PIOGLITAZONE$119,826
M01 · FY2006 · RR · contact PI
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$118,250
M01 · FY2006 · RR · contact PI
COMPARISON OF IN VITRO AND IN VIVO MEASURES OF INSULIN IN POLYCYSTIC OVARIES$102,483
M01 · FY2006 · RR · contact PI
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$34,687
M01 · FY2006 · RR · contact PI
12 WKS OF COLESEVELAM ON INSULIN SENSITIVITY AND ORAL GLUCOSE ABSORPTION$11,037
M01 · FY2006 · RR · contact PI
COMPARISON OF IN VITRO AND IN VIVO MEASURES OF INSULIN IN POLYCYSTIC OVARIES$220,402
M01 · FY2005 · RR
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$212,466
M01 · FY2005 · RR
COMBINATION THERAPY WITH ROSIGLITAZONE AND METFORMIN FOR TYPE 2 DIABETES$109,896
M01 · FY2005 · RR
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$47,622
M01 · FY2005 · RR
MECHANISMS OF EDEMA AND WEIGHT GAIN WITH PIOGLITAZONE$42,127
M01 · FY2005 · RR
Role of Glycogen Synthase Kinase 3 In Type 2-Diabetes$280,000
R01 · FY2004 · DK
In Vitro and in Vivo Measures of Insulin in PCOS$266,720
M01 · FY2004 · RR
Screening Study to Assess Eligibility for Metabolic Studies$113,297
M01 · FY2004 · RR
Glucose Metabolism And Insulin Action In Human Skeletal Muscle Culture$31,865
M01 · FY2004 · RR
Mechanisms of Edema and Weight Gain with Pioglitazone$28,324
M01 · FY2004 · RR
Combination Therapy of Rosiglitazone/Metformin for NIDDM$12,392
M01 · FY2004 · RR
Role of Glycogen Synthase Kinase 3 In Type 2-Diabetes$280,000
R01 · FY2003 · DK
Role of Glycogen Synthase Kinase 3 In Type 2-Diabetes$280,000
R01 · FY2002 · DK
INSULIN SENSITIVITY IN PCOS--EFFECT OF ROSIGLITAZONE$0
M01 · FY2002 · RR
BODY FAT DISTRIBUTION AND CARDIOVASCULAR RISK IN OBESITY AND NIDDM$0
M01 · FY2002 · RR
BODY FAT DISTRIBUTION AND CARDIOVASCULAR RISK IN OBESITY AND NIDDM$0
M01 · FY2002 · RR
BODY FAT DISTRIBUTION AND CARDIOVASCULAR RISK IN OBESITY AND NIDDM$0
M01 · FY2002 · RR
BODY FAT DISTRIBUTION AND CARDIOVASCULAR RISK IN OBESITY AND NIDDM$0
M01 · FY2002 · RR
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$0
M01 · FY2002 · RR
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$0
M01 · FY2002 · RR
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$0
M01 · FY2002 · RR
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$0
M01 · FY2002 · RR
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$0
M01 · FY2002 · RR
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$0
M01 · FY2002 · RR
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$0
M01 · FY2002 · RR
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$0
M01 · FY2002 · RR
EFFECTS OF DIETARY SUPPLEMENT ON GLUCOSE HOMEOSTASIS$0
M01 · FY2002 · RR
EFFECTS OF DIETARY SUPPLEMENT ON GLUCOSE HOMEOSTASIS$0
M01 · FY2002 · RR
EFFECTS OF DIETARY SUPPLEMENT ON GLUCOSE HOMEOSTASIS$0
M01 · FY2002 · RR
EFFECTS OF DIETARY SUPPLEMENT ON GLUCOSE HOMEOSTASIS$0
M01 · FY2002 · RR
TISSUE SPECIFIC EFFECTS OF TROGLITAZONE ON METAB. &GENE EXPRESSION$0
M01 · FY2002 · RR
TISSUE SPECIFIC EFFECTS OF TROGLITAZONE ON METAB. &GENE EXPRESSION$0
M01 · FY2002 · RR
TISSUE SPECIFIC EFFECTS OF TROGLITAZONE ON METAB. &GENE EXPRESSION$0
M01 · FY2002 · RR
TISSUE SPECIFIC EFFECTS OF TROGLITAZONE ON METAB. &GENE EXPRESSION$0
M01 · FY2002 · RR
PPAR RECEPTORS IN MECHANISM OF ACTION OF TROGLITAZONE$0
M01 · FY2002 · RR
PPAR RECEPTORS IN MECHANISM OF ACTION OF TROGLITAZONE$0
M01 · FY2002 · RR
PPAR RECEPTORS IN MECHANISM OF ACTION OF TROGLITAZONE$0
M01 · FY2002 · RR
PPAR RECEPTORS IN MECHANISM OF ACTION OF TROGLITAZONE$0
M01 · FY2002 · RR
WEIGHT LOSS IN GLUCOSE METABOLISM AND INSULIN ACTION$0
M01 · FY2002 · RR
WEIGHT LOSS IN GLUCOSE METABOLISM AND INSULIN ACTION$0
M01 · FY2002 · RR
WEIGHT LOSS IN GLUCOSE METABOLISM AND INSULIN ACTION$0
M01 · FY2002 · RR
WEIGHT LOSS IN GLUCOSE METABOLISM AND INSULIN ACTION$0
M01 · FY2002 · RR
INSULIN SENSITIVITY IN PCOS--EFFECT OF ROSIGLITAZONE$0
M01 · FY2002 · RR
INSULIN SENSITIVITY IN PCOS--EFFECT OF ROSIGLITAZONE$0
M01 · FY2002 · RR
INSULIN SENSITIVITY IN PCOS--EFFECT OF ROSIGLITAZONE$0
M01 · FY2002 · RR
Role of Glycogen Synthase Kinase 3 In Type 2-Diabetes$280,000
R01 · FY2001 · DK
PPAR RECEPTORS IN MECHANISM OF ACTION OF TROGLITAZONE$0
M01 · FY2001 · RR
PPAR RECEPTORS IN MECHANISM OF ACTION OF TROGLITAZONE$0
M01 · FY2001 · RR
TISSUE SPECIFIC EFFECTS OF TROGLITAZONE ON METAB. &GENE EXPRESSION$0
M01 · FY2001 · RR
TISSUE SPECIFIC EFFECTS OF TROGLITAZONE ON METAB. &GENE EXPRESSION$0
M01 · FY2001 · RR
EFFECTS OF DIETARY SUPPLEMENT ON GLUCOSE HOMEOSTASIS$0
M01 · FY2001 · RR
EFFECTS OF DIETARY SUPPLEMENT ON GLUCOSE HOMEOSTASIS$0
M01 · FY2001 · RR
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$0
M01 · FY2001 · RR
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$0
M01 · FY2001 · RR
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$0
M01 · FY2001 · RR
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$0
M01 · FY2001 · RR
BODY FAT DISTRIBUTION AND CARDIOVASCULAR RISK IN OBESITY AND NIDDM$0
M01 · FY2001 · RR
BODY FAT DISTRIBUTION AND CARDIOVASCULAR RISK IN OBESITY AND NIDDM$0
M01 · FY2001 · RR
INSULIN SENSITIVITY IN PCOS--EFFECT OF ROSIGLITAZONE$0
M01 · FY2001 · RR
INSULIN SENSITIVITY IN PCOS--EFFECT OF ROSIGLITAZONE$0
M01 · FY2001 · RR
WEIGHT LOSS IN GLUCOSE METABOLISM AND INSULIN ACTION$0
M01 · FY2001 · RR
WEIGHT LOSS IN GLUCOSE METABOLISM AND INSULIN ACTION$0
M01 · FY2001 · RR
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$0
M01 · FY2000 · RR
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$0
M01 · FY2000 · RR
GLUCOSE METABOLISM AND INSULIN ACTION IN HUMAN SKELETAL MUSCLE CULTURE$0
M01 · FY2000 · RR
BODY FAT DISTRIBUTION AND CARDIOVASCULAR RISK IN OBESITY AND NIDDM$0
M01 · FY2000 · RR
BODY FAT DISTRIBUTION AND CARDIOVASCULAR RISK IN OBESITY AND NIDDM$0
M01 · FY2000 · RR
BODY FAT DISTRIBUTION AND CARDIOVASCULAR RISK IN OBESITY AND NIDDM$0
M01 · FY2000 · RR
INSULIN SENSITIVITY IN PCOS--EFFECT OF ROSIGLITAZONE$0
M01 · FY2000 · RR
INSULIN SENSITIVITY IN PCOS--EFFECT OF ROSIGLITAZONE$0
M01 · FY2000 · RR
WEIGHT LOSS IN GLUCOSE METABOLISM AND INSULIN ACTION$0
M01 · FY2000 · RR
WEIGHT LOSS IN GLUCOSE METABOLISM AND INSULIN ACTION$0
M01 · FY2000 · RR
PPAR RECEPTORS IN MECHANISM OF ACTION OF TROGLITAZONE$0
M01 · FY2000 · RR
PPAR RECEPTORS IN MECHANISM OF ACTION OF TROGLITAZONE$0
M01 · FY2000 · RR
PPAR RECEPTORS IN MECHANISM OF ACTION OF TROGLITAZONE$0
M01 · FY2000 · RR
TISSUE SPECIFIC EFFECTS OF TROGLITAZONE ON METAB. &GENE EXPRESSION$0
M01 · FY2000 · RR
TISSUE SPECIFIC EFFECTS OF TROGLITAZONE ON METAB. &GENE EXPRESSION$0
M01 · FY2000 · RR
TISSUE SPECIFIC EFFECTS OF TROGLITAZONE ON METAB. &GENE EXPRESSION$0
M01 · FY2000 · RR
EFFECTS OF DIETARY SUPPLEMENT ON GLUCOSE HOMEOSTASIS$0
M01 · FY2000 · RR
EFFECTS OF DIETARY SUPPLEMENT ON GLUCOSE HOMEOSTASIS$0
M01 · FY2000 · RR
EFFECTS OF DIETARY SUPPLEMENT ON GLUCOSE HOMEOSTASIS$0
M01 · FY2000 · RR
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$0
M01 · FY2000 · RR
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$0
M01 · FY2000 · RR
SCREENING STUDY TO ASSESS ELIGIBILITY FOR METABOLIC STUDIES$0
M01 · FY2000 · RR